Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2000 Nov;37(11):817-27.
doi: 10.1136/jmg.37.11.817.

Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis

J R Hansford  1 , L M Mulligan
Affiliations
Review

Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis

J R Hansford et al. J Med Genet. 2000 Nov.

Abstract

Multiple endocrine neoplasia type 2 (MEN 2) is an inherited cancer syndrome characterised by medullary thyroid carcinoma (MTC), with or without phaeochromocytoma and hyperparathyroidism. MEN 2 is unusual among cancer syndromes as it is caused by activation of a cellular oncogene, RET. Germline mutations in the gene encoding the RET receptor tyrosine kinase are found in the vast majority of MEN 2 patients and somatic RET mutations are found in a subset of sporadic MTC. Further, there are strong associations of RET mutation genotype and disease phenotype in MEN 2 which have led to predictions of tissue specific requirements and sensitivities to RET activity. Our ability to identify genetically, with high accuracy, subjects with MEN 2 has revolutionised our ability to diagnose, predict, and manage this disease. In the past few years, studies of RET and its normal ligand and downstream interactions and the signalling pathways it activates have clarified our understanding of the roles played by RET in normal cell survival, proliferation, and differentiation, as well as in disease. Here, we review the current knowledge of the normal functions of RET and the effects of mutations of this gene in tumorigenesis and in normal development.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Clin Oncol. 1999 Jan;17(1):380-93 - PubMed
    1. Endocrinology. 1999 Sep;140(9):3992-8 - PubMed
    1. Am J Hum Genet. 1999 Nov;65(5):1469-73 - PubMed
    1. J Med Genet. 1999 Oct;36(10):771-4 - PubMed
    1. J Neurosci. 1999 Nov 1;19(21):9160-9 - PubMed

MeSH terms

Substances

LinkOut - more resources